2026-2034年全球血栓症治療市場規模、佔有率、趨勢和成長分析報告

預計血栓症治療市場規模將從 2025 年的 408.7 億美元成長到 2034 年的 750 億美元，2026 年至 2034 年的複合年成長率為 6.98%。

受心血管疾病和血液凝固障礙發病率上升的推動，全球血栓症治療市場正經歷強勁成長。深層靜脈栓塞症、肺動脈栓塞和心房顫動病例的增加顯著提升了對凝血劑和溶栓療法的需求。人口老化也進一步增強了市場前景。

關鍵成長要素包括新型口服抗凝血劑（NOAC）的進步、診斷能力的提升以及健康意識宣傳活動的擴展。久坐的生活方式和不斷上升的肥胖率也增加了血栓症的風險，從而推高了藥物需求。此外，有利的醫療保險政策和持續的臨床研究也在加速市場擴張。

展望未來，研發出更安全、更有效的抗凝血劑，降低出血風險，預計將惠及市場。研發投入的增加和不斷擴充的藥物研發管線將推動進一步的創新。新興市場可望憑藉醫療服務的可近性和疾病意識的提高，提供巨大的成長機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球血栓症治療市場：依藥物類別分類

• 市場分析、洞察與預測
• Xa因子抑制劑
• 低分子量肝素
• P2Y12血小板抑制劑
• 其他

第5章 全球血栓症治療市場：依適應症分類

• 市場分析、洞察與預測
• 肺動脈栓塞
• 心房顫動
• 深層靜脈栓塞症
• 其他

第6章 全球血栓症治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球血栓症治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • GSK Plc
  • Baxter International Inc
  • Johnson & Johnson
  • Sanofi
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • Bayer AG
  • Aspen Pharmacare Holdings Limited
  • Boehringer Ingelheim GmbH
  • Pfizer Inc

The Thrombosis Drugs Market size is expected to reach USD 75.00 Billion in 2034 from USD 40.87 Billion (2025) growing at a CAGR of 6.98% during 2026-2034.

The Global Thrombosis Drugs Market is experiencing robust growth driven by the increasing incidence of cardiovascular diseases and blood clotting disorders. Rising cases of deep vein thrombosis, pulmonary embolism, and atrial fibrillation are significantly contributing to the demand for anticoagulants and thrombolytic therapies. The growing aging population further strengthens the market outlook.

Major growth drivers include advancements in novel oral anticoagulants (NOACs), improved diagnostic capabilities, and expanding healthcare awareness programs. Increasing sedentary lifestyles and obesity rates are also contributing to higher thrombosis risks, thereby boosting drug demand. Additionally, favorable reimbursement policies and ongoing clinical research are accelerating market expansion.

Looking ahead, the market is expected to benefit from the development of safer and more effective anticoagulant drugs with reduced bleeding risks. Increasing R&D investments and expansion of pharmaceutical pipelines will further drive innovation. Emerging markets are anticipated to provide substantial growth opportunities due to improving healthcare access and rising disease awareness.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Factor Xa Inhibitor
• Low Molecular Weight Heparin
• P2Y12 Platelet Inhibitor
• Others

By Indication

• Pulmonary Embolism
• Atrial Fibrillation
• Deep Vein Thrombosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• GSK plc, Baxter International Inc, Johnson Johnson, Sanofi, BristolMyers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, Pfizer Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL THROMBOSIS DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Factor Xa Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Low Molecular Weight Heparin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. P2Y12 Platelet Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL THROMBOSIS DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Pulmonary Embolism Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Atrial Fibrillation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Deep Vein Thrombosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL THROMBOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL THROMBOSIS DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL THROMBOSIS DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 GSK Plc
  • 9.2.2 Baxter International Inc
  • 9.2.3 Johnson & Johnson
  • 9.2.4 Sanofi
  • 9.2.5 Bristol-Myers Squibb Company
  • 9.2.6 AstraZeneca Plc
  • 9.2.7 Bayer AG
  • 9.2.8 Aspen Pharmacare Holdings Limited
  • 9.2.9 Boehringer Ingelheim GmbH
  • 9.2.10 Pfizer Inc